Abstract

Cholangiocarcinoma is a malignant tumor that originates from biliary epithelial cells. Its early symptoms are atypical. When a definitive diagnosis is achieved, it is often already at middle and late stages, and the prognosis is poor. It is difficult to obtain a balance between sensitivity and specificity in current laboratory tests. Therefore, the search for new molecular markers, especially suitable biomolecules that can be conveniently obtained from blood, bile and other body fluids, is of great significance for the clinical diagnosis and treatment of the disease. With the rapid development of genomics, epigenetics, transcriptomics, proteomics, metabolomics, and radiomics, these studies have entered a new phase. Researchers have discovered some potential biomolecules expected to be used for the early diagnosis and prognosis assessment of the disease. This article reviews the currently-obtained molecular markers of cholangiocarcinoma to provide reference for further research and application. Key words: Cholangiocarcinoma; Biomarkers; Genomics; Epigenetics; Transcriptomics; Proteomics; Metabolomics; Radiomics

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.